The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 12 October 2026.
Announcements
185
Total raised
£13.6B
disclosed amounts
The financing values the biotechnology company at $800m and will support its in vivo cell therapy pipeline.
"We believe the future of medicine lies in reprogramming the body to repair itsel. We design the models and the medicines to teach it howf"
Most rounds here started life as a press release.
Winfred reads them overnight, pulls out the facts, checks them against Companies House and files them. It was built by C8VA, who do the same kind of work for other businesses: turning messy, unstructured material into something you can search, count and rely on.
The $300m Series C values the defence tech startup at $3.4bn following backing from DFJ Growth.
"This raise is testament to the incredible work of the entire Cambridge Aerospace team. The addition of these funds will allow us to continue to scale our manufacturing and our delivery to meet the pace of threats, and the needs of Allied nations,"
The Series C round was co-led by Oxford Science Enterprises and Supernova Invest to support product development.
"When we helped spin Moa out from the University of Oxford’s Plant Sciences Department in 2017, we saw that its technology platform had a unique and important approach to address the market’s need for herbicides capable of breaking weed resistance,"
The London-based health technology provider has raised £30m led by Revaia to expand its infrastructure across Europe.
"For years, the industry has tried to address complex systemic issues through disconnected point solutions, but fragmented technology often adds operational complexity for healthcare providers and creates an interrupted experience for patients. What healthcare organisations need is intelligent orchestration across the entire care journey. The practices and groups that win over the next decade will be the ones that deliver the best patient experience end-to-end."

Bullhound Capital led the Series C financing, which stands as Europe's largest private quantum funding round.
"Globally, it represents a clear shift in the market from long-term promise to near-term delivery in quantum computing. For OQC, this gives us the capital to scale internationally, advance our technology roadmap, and meet increasing demand from customers seeking secure, scalable access to quantum computing infrastructure."